Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

计划入组 30 人 · 首次发布于 2022 年 12 月 30 日

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

计划入组 70 人 · 首次发布于 2022 年 2 月 16 日

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

计划入组 77 人 · 首次发布于 2020 年 2 月 21 日

RET kinase inhibitors (lung/thyroid/pancreatic cancer)

Ret tyrosine kinase receptor inhibitor (lung cancer/thyroid cancer)

Thyroid, porcine

FUSION PHARMACEUTICALS

Nepal

Biomea Fusion

United States

Fusion Pharmaceuticals Inc.

CStone Pharmaceuticals Receives NMPA Approval for Local Manufacturing of RET Inhibitor GAVRETO in China

Final ARROW Study Data Shows Pralsetinib Achieves 70% Response Rate in RET+ NSCLC with Durable Survival Outcomes

RET Fusion Targeted Therapies Market Projected for Significant Growth Through 2034